Long term prospective follow-up study of tocilizumab (RoActermraR) administered to patients with rheumatoid arthritis in daily clinical practice.

Long term prospective follow-up study of tocilizumab (RoActermraR) administered to patients with rheumatoid arthritis in daily clinical practice. - tocilizumab in rheumatoid arthritis

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON34333

Enrollment

200

Registered

2010-04-28

Start date

2010-08-25

Completion date

Unknown

Last updated

2024-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

inflammatory disease

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: rheumatoid arthritis and treatment with tocilizumab

Exclusion criteria

Exclusion criteria: contraindications for treatment with tocilizumab No signed informed consent

Design outcomes

Primary

Measure	Time frame
Efficacy will be determined in comparison to baseline by comparing disease activity, radiological progression and functional capacity during follow-up. Safety will be determined by the occurrence of (serious) side effects.	—

Secondary

Measure	Time frame
There will be a particular focus of the effect of tocilizumab on lipid profile, bone density changes as well as risk factors for cardiovascular disease and osteoporosis. prognostic determinators will be assessed.	—

Countries

Netherlands

Outcome results